CTOs on the Move

Cadence Neuroscience

www.cadenceneuro.com

 
Cadence Neuroscience is developing a next generation implantable device therapy for epilepsy. The therapy, pioneered by researchers at Mayo Clinic over the past decade, uses advanced methods to provide individualized treatment for each patient. Our core technology includes a specialized neuromodulation platform that enables these methods. Cadence is currently engaged in the engineering and testing of the platform, and preparing for additional clinical evaluations.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Cadence Neuroscience raised $20M on 10/11/2019

Similar Companies

Cornerstone BioPharma

At Cornerstone BioPharma, we are constantly striving to make good medicines better. We know that Healthcare providers and patients are concerned about the safety of today's medications-that makes tried and true medications very appealing. However, due to

Neuraptive Therapeutics

Neuraptive is bringing novel therapeutic technology for the acute surgical repair of injured peripheral nerves.

Solugen

Solugen is a venture-backed biotech startup that replaces petroleum based products with plant-derived substitutes.

Conversant Biologics

Conversant Biologics is a Huntsville, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Melinta

Melinta Therapeutics, Inc. (NASDAQ:MLNT) is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new therapeutic solutions. Its four marketed products include Baxdela™ (delafloxacin), Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. It also has an extensive pipeline of preclinical and clinical-stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections.